Back to Journals » Journal of Blood Medicine » Volume 1

Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL)

Authors Al-Kali, Wierda WG, Keating M, O'Brien S

Published 21 June 2010 Volume 2010:1 Pages 115—122


Review by Single-blind

Peer reviewer comments 3

Aref Al-Kali, William Wierda, Michael Keating, Susan O’Brien

Leukemia Department, UT MD Anderson Cancer Center, Houston, Texas, USA

Abstract: Patients with chronic lymphocytic leukemia (CLL) have benefited from the introduction of targeted therapy for leukemia. Rituximab (a chimeric murine-derived monoclonal antibody that targets CD20 on lymphocytes) was the first monoclonal antibody to affect the natural course of this disease. Several reports have shown modest single-agent activity in patients with CLL. However, the best results come from the combination of this agent with chemotherapy; a significant benefit has been seen with the use of fludarabine, cyclophosphamide, and rituximab (FCR). The addition of rituximab to chemotherapy boosted overall response rates, complete response rates and prolonged progression free survival. Recent data showed an overall survival benefit with FCR. Other combinations including bendamustine and rituximab appear more effective than bendamustine alone, while combining rituximab with other types of agents also appears to improve response rates. This type of relatively nontoxic regimen is being investigated in elderly patients who may not tolerate standard combination chemoimmunotherapies.
Keywords: chronic lymphocytic leukemia, rituxan, bioimmunotherapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]